AZ Health review

AZ Health advertises an NAD⁺ starting price before intake. That helps identify an offer, but the asterisk does not establish dose, supply or a complete payment contract. Its homepage also gives conflicting injectable tirzepatide figures. The pharmacy, clinician and public legal-policy links remain unconfirmed, so request those details before providing payment or health information.

AZ Health, also branded AZHM, presents virtual care associated with Phoenix and Chandler, Arizona. The homepage lists NAD⁺ injections and injectable and oral dissolving weight-loss products. Its approximately half-of-states coverage counter and Arizona footer do not establish an exact treatment-eligibility list. Certification and professional-supervision statements are seller claims rather than independent verification.

The page describes a free 20-minute screening phone call and nurse-practitioner review within 24 hours, without naming an individual clinician, treating legal group or dispensing pharmacy. It advertises ongoing check-ins and free discreet shipping. NAD⁺ lab requirements, visit inclusions and eligibility still need confirmation. No insurance is required; FSA/HSA eligibility is marketed without establishing individual reimbursement. Public navigation and footer did not expose legal-policy links. Cancel-anytime and no-contract marketing does not establish a cancellation deadline or processed-order refund.

NAD⁺ injection is advertised from $249/month with an asterisk and a new-patient qualifier, without a stated dose, supply or complete charge. Confirm how long the starting rate lasts, billing timing, renewal, visit/lab costs and refunds. On the separate weight-loss line, the injectable tirzepatide card says $199/month while the expanded cost FAQ says $249/month. Oral tablet prices and their 30-tablet quantities do not establish NAD⁺ supply.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Confirm the actual formulation and dispensing pharmacy. On the evidence, the NAD⁺ product needs stating flatly: injected NAD⁺ has no controlled human outcome trials supporting the energy, focus or longevity claims the category runs on, and the single human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears from plasma quickly. The NAD⁺ forms with human trial data are the oral precursors NR and NMN, and what those trials establish is a raised blood NAD⁺ level, not an improved outcome. Individual results vary.